The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged with a third new direct-acting antiviral agent (dasabuvir) in a second tablet, for oral treatment of chronic hepatitis C virus (HCV) genotype 1 infection (Table 1). Genotype 1 is responsible for 70%-80% of HCV infections in the US.
A 4-Drug Combination (Viekira Pak) for Hepatitis C. JAMA. 2015;313(18):1857–1858. doi:10.1001/jama.2015.4562
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: